Form 4: Terns Pharmaceuticals Director David A. Fellows Acquires 32,000 Stock Options

Director David A. Fellows of Terns Pharmaceuticals acquired 32,000 stock options on June 10, 2024, with vesting terms tied to the first anniversary of the grant date or the next Annual Meeting.

Summary

• David A. Fellows, a director of Terns Pharmaceuticals, acquired 32,000 stock options on June 10, 2024.
• The exercise price of these options is $6.99.
• The options vest fully on the earlier of the first anniversary of the grant date or immediately prior to the Annual Meeting following the grant date.
• The options expire on June 9, 2034.
• Following the transaction, Fellows directly owns 32,000 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it simply reports a transaction. The acquisition of options by a director is generally viewed as a slightly positive signal, but it's a routine event.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in the pharmaceutical industry as part of executive compensation packages.

Stakeholder Impact

• The acquisition of stock options by a director could have a minor positive impact on shareholder sentiment.

Key Dates